循环 GPIHBP1 水平与 2 型糖尿病患者微血管并发症的关系：一项横断面研究。

Circulating GPIHBP1 levels and microvascular complications in patients with type 2 diabetes: A cross-sectional study.

机构信息

Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan (Drs Kurooka, Eguchi, Yamaguchi, Nojima, Nakatsuka, Wada).

出版信息

J Clin Lipidol. 2022 Mar-Apr;16(2):237-245. doi: 10.1016/j.jacl.2022.01.006. Epub 2022 Jan 19.

DOI:10.1016/j.jacl.2022.01.006

PMID:35101360

Abstract

BACKGROUND

Glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 (GPIHBP1) plays a crucial role in lipolytic processing. Previous studies have shown that GPIHBP1 mutations cause severe hypertriglyceridemia and that serum GPIHBP1 levels are marginally higher in patients with coronary heart disease; however, the role of GPIHBP1 in type 2 diabetes mellitus (T2DM) remains unknown.

OBJECTIVE

We investigated the association between circulating GPIHBP1 levels and the prevalence of microvascular complications in T2DM.

METHODS

A total of 237 subjects with T2DM and 235 non-diabetic control subjects were enrolled in this study. Their serum GPIHBP1 levels were evaluated using ELISA assays.

RESULTS

Circulating GPIHBP1 levels were higher in patients with T2DM (952.7 pg/mL [761.3-1234.6], p < 0.0001) than in non-diabetic subjects (700.6 [570.8-829.6]), but did not differ in T2DM patients with or without hypertriglyceridemia. Serum GPIHBP1 levels were significantly higher in patients with T2DM with diabetic retinopathy (DR), diabetic nephropathy (DN), and microvascular complications than in those without these complications. Multivariable logistic regression and receiver operating characteristic (ROC) curve analyses revealed that the presence of microvascular complications, but not macrovascular complications, was independently associated with serum GPIHBP1 levels, which could predict the presence of diabetic microvascular complications.

CONCLUSIONS

Elevated GPIHBP1 levels are associated with microvascular complications in T2DM and may help to predict their progression.

摘要

背景

糖基磷脂酰肌醇锚定高密度脂蛋白结合蛋白 1（GPIHBP1）在脂肪酶加工中起着至关重要的作用。先前的研究表明，GPIHBP1 突变会导致严重的高甘油三酯血症，冠心病患者的血清 GPIHBP1 水平略高；然而，GPIHBP1 在 2 型糖尿病（T2DM）中的作用尚不清楚。

目的

我们研究了循环 GPIHBP1 水平与 T2DM 微血管并发症患病率之间的关系。

方法

本研究共纳入 237 例 T2DM 患者和 235 例非糖尿病对照者。采用 ELISA 法检测其血清 GPIHBP1 水平。

结果

T2DM 患者的循环 GPIHBP1 水平高于非糖尿病者（952.7 pg/mL[761.3-1234.6]，p<0.0001），但无论是否伴有高甘油三酯血症，T2DM 患者之间并无差异。合并糖尿病视网膜病变（DR）、糖尿病肾病（DN）和微血管并发症的 T2DM 患者的血清 GPIHBP1 水平显著高于无这些并发症的患者。多变量逻辑回归和受试者工作特征（ROC）曲线分析显示，微血管并发症的存在而非大血管并发症的存在与血清 GPIHBP1 水平独立相关，血清 GPIHBP1 水平可预测糖尿病微血管并发症的发生。